Shenzhen Salubris Pharmaceuticals Co.,Ltd.(002294),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

002294 Shenzhen Salubris Pharmaceuticals Co.,Ltd.

Closed 12-22 15:00:00

56.20

-0.18

-0.32%

High56.75	Low55.85	Vol3.18M
Open56.28	D1 Closing56.38	Amplitude1.60%
Mkt Cap62.66B	Tradable Cap62.66B	Total Shares1.12B
T/O179.00M	T/O Rate0.28%	Tradable Shares1.12B
P/B7.16	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"Shenzhen Salubris Pharmaceuticals Co.,Ltd.","latestPrice":56.2,"timestamp":1766387037000,"preClose":56.38,"halted":0,"volume":3176909,"delay":0,"changeRate":-0.0032,"floatShares":1115000000,"shares":1115000000,"eps":0.6033,"marketStatus":"Closed","change":-0.18,"latestTime":"12-22 15:00:00","open":56.28,"high":56.75,"low":55.85,"amount":179000000,"amplitude":0.016,"askPrice":56.25,"askSize":1,"bidPrice":56.2,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.6033,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":5,"adr":0,"adjPreClose":56.38,"symbolType":"stock","openAndCloseTimeList":[[1766367000000,1766374200000],[1766379600000,1766386800000]],"highLimit":62.02,"lowLimit":50.74,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":7.16,"roa":"--","peRate":93.154318,"roe":"6.67%","epsLYR":0.54,"committee":0.742373,"marketValue":62653000000,"turnoverRate":0.0029,"status":1,"floatMarketCap":62639000000},"requestUrl":"/m/hq/s/002294/tweets","defaultTab":"tweets","newsList":[{"id":"1126058216","title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): SAL0137 Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1126058216","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126058216?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:44","pubTimestamp":1766137496,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The approval...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002294","BK0028","BK0196","BK0187","BK0188","BK0183","BK0239"],"gpt_icon":0},{"id":"2590763592","title":"BRIEF-Shenzhen Salubris Pharmaceuticals Plans To Seek Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590763592","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590763592?lang=en_us&edition=fundamental","pubTime":"2025-12-11 18:42","pubTimestamp":1765449778,"startTime":"0","endTime":"0","summary":"BRIEF-Shenzhen Salubris Pharmaceuticals Plans To Seek Hong Kong ListingDec 11 (Reuters) - Shenzhen Salubris Pharmaceuticals Co Ltd 002294.SZ:SAYS CO PLANS TO SEEK HONG KONG LISTINGSource textFurther company coverage: 002294.SZ (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL4N3XH0QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0028","BK0183","002294","BK0239","BK0187","BK0188"],"gpt_icon":0},{"id":"2590592734","title":"Shenzhen Salubris Pharmaceuticals  Says Co Plans to Seek Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590592734","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590592734?lang=en_us&edition=fundamental","pubTime":"2025-12-11 18:42","pubTimestamp":1765449778,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL4N3XH0QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0028","BK0239","002294","BK0187","BK0196","BK0183"],"gpt_icon":0},{"id":"2590949783","title":"Salubris Pharmaceuticals' Three Drugs Placed in China's Medical Insurance Catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2590949783","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590949783?lang=en_us&edition=fundamental","pubTime":"2025-12-09 13:09","pubTimestamp":1765256948,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals'  three drugs were included in China's National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog, according to a Shenzhen bourse filing on Tuesday.Xinchaotuo or sacubitril and alisartan calcium tablets and Fulian or alisartan ester and indapamide sustained-release tablets were newly included in the list, while Enaro or ennadustat tablets were renewed and retained.Meanwhile, Xilitan or alisartan tablets were adjusted to routine management under the catalog.The catalog will be valid between Jan. 1, 2026, and Dec. 31, 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0188","BK0196","BK0187","002294","BK0028","BK0239"],"gpt_icon":0},{"id":"2590948603","title":"Salubris Pharmaceuticals Gets Nod to Trial Hyperaldosteronism Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2590948603","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590948603?lang=en_us&edition=fundamental","pubTime":"2025-12-09 12:52","pubTimestamp":1765255975,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals (SHE:002294) received approval from China's National Medical Products Administration to conduct clinical trials on SAL0140 tablets, according to a Shenzhen bourse filing on Tuesday.The drug will be tested as a treatment for hyperaldosteronism.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002294","BK0183","BK0188","BK0028","BK0196","BK0239","BK0187"],"gpt_icon":0},{"id":"1182851781","title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): XinChaoTuo, FuLiAn, and EnNaLuo Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1182851781","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182851781?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:14","pubTimestamp":1765185263,"startTime":"0","endTime":"0","summary":"According to the announcement by Shenzhen Salubris Pharmaceuticals (002294.SZ), the National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","002294","BK0028","BK0196","BK0183","BK0187"],"gpt_icon":0},{"id":"2588107615","title":"Shenzhen Salubris Pharmaceuticals Gets China Approval for Chronic Kidney Disease Tablet Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2588107615","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588107615?lang=en_us&edition=fundamental","pubTime":"2025-12-04 09:23","pubTimestamp":1764811406,"startTime":"0","endTime":"0","summary":"Chinese drug regulators approved Shenzhen Salubris Pharmaceuticals'  clinical trials for its SAL0140 chronic kidney disease tablets, according to a Thursday filing with the Shenzhen bourse.The drug is an aldosterone synthase inhibitor that maintains fluid and electrolyte balance, helping reduce end-organ damage, according to the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0188","BK0196","BK0187","002294","BK0028","BK0239"],"gpt_icon":0},{"id":"1119603610","title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): Innovative Small-Molecule Drug SAL0139 Approved for Clinical Trials in Hyperlipidemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1119603610","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119603610?lang=en_us&edition=fundamental","pubTime":"2025-11-21 16:08","pubTimestamp":1763712517,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it recently received the Clinical Trial Approval Notice issued by the National Medical Products Administration. The approval...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","BK0183","BK0196","BK0187","BK0028","002294"],"gpt_icon":0},{"id":"2578398223","title":"Salubris Pharmaceuticals Q3 Profit Up 31%, Revenue Rises 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578398223","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578398223?lang=en_us&edition=fundamental","pubTime":"2025-10-28 15:33","pubTimestamp":1761636833,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals  posted third-quarter attributable net profit of 215.6 million yuan, up 31% from the previous year.Earnings per share rose 27% to 0.19 yuan, according to a Tuesday filing with the Shanghai bourse.Operating revenue climbed 16% year over year to 1.11 billion yuan.Shares of the pharmaceutical company climbed 1% Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0183","BK0187","002294","BK0028","BK0239","BK0196"],"gpt_icon":0},{"id":"2575432967","title":"Shenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2575432967","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575432967?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:53","pubTimestamp":1760615588,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals  obtained the acceptance of China's drug administrator for clinical trials for SAL0137 tablets.SAL0137 has the potential to treat elevated lipoprotein , a risk factor for cardiovascular diseases like heart attacks and strokes, according to a Thursday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 3% higher Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","002294","BK0028","BK0196","BK0239","BK0183","BK0187"],"gpt_icon":0},{"id":"1127102985","title":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) Receives Acceptance for Clinical Trial Application of SAL0137","url":"https://stock-news.laohu8.com/highlight/detail?id=1127102985","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127102985?lang=en_us&edition=fundamental","pubTime":"2025-10-15 17:34","pubTimestamp":1760520857,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it has received an acceptance notice from the National Medical Products Administration for its clinical trial application. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0187","BK0028","BK0183","BK0239","BK0196","002294"],"gpt_icon":0},{"id":"2571039736","title":"Shenzhen Salubris Pharmaceuticals Gets Regulatory Acceptance for Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2571039736","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571039736?lang=en_us&edition=fundamental","pubTime":"2025-09-30 12:54","pubTimestamp":1759208068,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals  said China's drug administrator has accepted its clinical trial application for a new indication for self-developed SAL0140 tablets.The application seeks to investigate SAL0140 for treating primary aldosteronism, one of the common causes of secondary hypertension, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["002294","BK0028","BK0196","BK0183","BK0239","BK0187","BK0188"],"gpt_icon":0},{"id":"1115334022","title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for SAL0140 Drug Receives Regulatory Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1115334022","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115334022?lang=en_us&edition=fundamental","pubTime":"2025-09-29 17:35","pubTimestamp":1759138549,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company recently received an acceptance notice issued by the National Medical Products Administration. The clinical trial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0187","BK0188","BK0028","002294","BK0239","BK0196"],"gpt_icon":0},{"id":"2569780411","title":"Salubris Pharmaceuticals Gets China Marketing Approval for High Cholesterol Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2569780411","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569780411?lang=en_us&edition=fundamental","pubTime":"2025-09-22 21:45","pubTimestamp":1758548738,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved Shenzhen Salubris Pharmaceuticals'  marketing of its Taikosizumab injection for high cholesterol and mixed dyslipidemia, according to a Saturday filing with the Shenzhen bourse.Shares closed 1% higher on Monday.The injection is administered via a single shot every four weeks, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","002294","BK0188","BK0196","BK0239","BK0187","BK0028"],"gpt_icon":0},{"id":"1151097243","title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for SAL0139 Drug Approved for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1151097243","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151097243?lang=en_us&edition=fundamental","pubTime":"2025-09-05 19:24","pubTimestamp":1757071453,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company has received an acceptance notice approved and issued by the National Medical Products Administration. The clinical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0239","BK0187","002294","BK0188","BK0183","BK0028"],"gpt_icon":0},{"id":"1183065297","title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): Clinical Trial Application for Self-Developed Innovative Small Molecule Drug SAL0140 Tablet Receives Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1183065297","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183065297?lang=en_us&edition=fundamental","pubTime":"2025-08-28 16:14","pubTimestamp":1756368897,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) announced that the company recently received an acceptance notice approved and issued by the National Medical Products Administration. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0239","BK0187","002294","BK0188","BK0183","BK0028"],"gpt_icon":0},{"id":"2560179366","title":"Shenzhen Salubris Pharmaceuticals' Attributable Profit Jumps 6% in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2560179366","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560179366?lang=en_us&edition=fundamental","pubTime":"2025-08-20 17:33","pubTimestamp":1755682419,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals'  attributable profit rose 6.1% to 365.1 million yuan in the first half from 344.1 million yuan in the year-ago period, according to a Wednesday filing with the Shenzhen bourse.Earnings per share at the drug company grew 6.5% to 0.33 yuan from 0.31 yuan in the prior-year period.Operating income increased 4.3% to 2.13 billion yuan from 2.04 billion yuan in the year-ago period.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0028","002294","BK0183","BK0239","BK0187","BK0196"],"gpt_icon":0},{"id":"1126193227","title":"Shenzhen Salubris Pharmaceuticals Releases Half-Year Report with Net Profit Up 6.1% in First Half","url":"https://stock-news.laohu8.com/highlight/detail?id=1126193227","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126193227?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:21","pubTimestamp":1755602498,"startTime":"0","endTime":"0","summary":"On August 19, Shenzhen Salubris Pharmaceuticals Co.,Ltd. released its half-year report. According to the announcement, the company's half-year operating revenue reached 2,130,967,669.97 yuan,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0239","BK0187","BK0188","BK0196","002294","BK0028"],"gpt_icon":0},{"id":"1162375176","title":"Shenzhen Salubris Pharmaceuticals Reports First Half Results with Net Profit of 365 Million Yuan, Up 6.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162375176","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162375176?lang=en_us&edition=fundamental","pubTime":"2025-08-19 18:44","pubTimestamp":1755600259,"startTime":"0","endTime":"0","summary":"Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) released its 2025 interim report, showing operating revenue of 2.131 billion yuan, representing a year-on-year increase of 4.32%. Net profit...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0196","BK0188","BK0028","BK0183","002294","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","stockEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0649},{"period":"3month","weight":0.0263},{"period":"6month","weight":0.2078},{"period":"1year","weight":0.7357},{"period":"ytd","weight":0.8406}],"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","perCapita":"44249股","boardName":"医药制造业","registeredCapital":"111481万元","compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0215},{"period":"3month","weight":0.025},{"period":"6month","weight":0.1335},{"period":"1year","weight":0.1631},{"period":"ytd","weight":0.1687}],"survey":"　　深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。","serverTime":1766445941911,"listedPrice":41.98,"stockholders":"25188人(较上一季度增加4.87%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shenzhen Salubris Pharmaceuticals Co.,Ltd.(002294),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shenzhen Salubris Pharmaceuticals Co.,Ltd.(002294) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shenzhen Salubris Pharmaceuticals Co.,Ltd.,002294,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股票,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股票老虎,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股票老虎国际,Shenzhen Salubris Pharmaceuticals Co.,Ltd.行情,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股票行情,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股价,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股市,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股票价格,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股票交易,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股票购买,Shenzhen Salubris Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shenzhen Salubris Pharmaceuticals Co.,Ltd.(002294),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shenzhen Salubris Pharmaceuticals Co.,Ltd.(002294) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}